ASH Annual Meeting and Exposition | Conference

Carfilzomib Bests Bortezomib Across Multiple Myeloma Subgroups

December 5th 2015

Treatment with carfilzomib reduced the risk of progression or death by 47% compared with bortezomib for patients with relapsed multiple myeloma.

Dr. Wierda on Combination Regimens With Venetoclax in CLL

December 4th 2015

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses two combination studies with venetoclax for patients with chronic lymphocytic leukemia (CLL) during the 2015 ASH Annual Meeting.

Dr. Usmani on Ibrutinib/Carfilzomib in Patients With Multiple Myeloma

December 4th 2015

Saad Z. Usmani, MD, hematology and medical oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses results of a phase Ib/II study examining the combination of ibrutinib plus carfilzomib in patients with relapsed/refractory multiple myeloma.

Dr. van den Brink Highlights Four Abstracts From ASH 2015

December 3rd 2015

Marcel R.M. van den Brink, MD, PhD, provides an overview of four notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

ASH 2015 Preview: Novel Agents, Combinations Abound Across Hematologic Malignancies

December 3rd 2015

In less than 5 years, the treatment landscape for patients with hematologic malignancies has undergone a dramatic transformation, with continued advancements and pivotal data being presented at the 2015 ASH Annual Meeting.

Pomalidomide Shows Benefits in Trials Testing New Combinations

January 20th 2015

Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.

Multiple Myeloma Advances: Noted Hematologist Envisions Big Changes in Treatment Paradigms

January 20th 2015

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years. Yet another revolution appears right around the corner.

Dr. LaCasce on Treating Relapsed/ Refractory Hodgkin Lymphoma with Brentuximab Vedotin Combo

December 16th 2014

Ann LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma.

Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALL

December 16th 2014

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Duvelisib Produces Responses in Indolent Non-Hodgkin Lymphoma

December 16th 2014

Duvelisib (IPI-145), an inhibitor of PI3K-Î´ and PI3K-Î³ signaling, had a favorable risk:benefit profile in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) in a phase I study, reported Ian Flinn, MD, PhD

Tyrosine Kinase Inhibitor Shows Promise in AML

December 15th 2014

Treatment with the TKI sorafenib in combination with standard chemotherapy increased event-free survival by 11.3 months compared with standard chemotherapy plus placebo in patients with newly diagnosed acute myeloid leukemia.

BCL-2 Inhibitor Venetoclax Demonstrates Activity in Pretreated AML

December 9th 2014

Some patients with heavily treated acute myelogenous leukemia benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199).

Brentuximab Vedotin Combination Shows Promise in Hodgkin Lymphoma

December 9th 2014

Ninety-six percent of patients with relapsed or refractory Hodgkin lymphoma who received treatment with the combination of brentuximab vedotin and bendamustine responded to treatment without experiencing dose-limiting toxicity.

Ibrutinib Combination Produces High Response Rate in Relapsed/Refractory MCL

December 9th 2014

Almost 90% of patients with relapsed or refractory mantle cell lymphoma responded to the targeted combination of ibrutinib and rituximab.

Dr. Ian Flinn Discusses Duvelisib Monotherapy in iNHL

December 9th 2014

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Jia Ruan Discusses Lenalidomide Plus Rituximab in MCL

December 9th 2014

Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for MCL.

Stem Cell Transplant Feasible, Highly Effective for HIV-Associated Lymphoma

December 8th 2014

Patients with HIV-associated lymphoma can effectively be treated with autologous hematopoietic stem cell transplantation, with outcomes that are similar to patients without HIV.

Dr. Raje Discusses Anti-CD38 Antibodies in Myeloma

December 8th 2014

Noopur Raje, MD, from the Multiple Myeloma Program at Massachusetts General Hospital, discusses the unprecedented efficacy seen with monoclonal antibodies as treatments for patients with multiple myeloma.

Elotuzumab Produces Impressive Response Rate in Relapsed/Refractory Multiple Myeloma

December 8th 2014

Treatment with elotuzumab in combination with lenalidomide and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma.

Nilotinib Shows Efficacy in Phase II Analysis of Elderly Patients With Philadelphia-Positive ALL

December 8th 2014

Treatment with nilotinib in combination with chemotherapy elicited complete hematological remissions in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.